Examples of using Entecavir in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Altered renal function contributed to the increase in entecavir exposure in these patients see section 4.4.
Adverse reactions considered at least possibly related to treatment with entecavir are listed by body system organ class.
Therefore, entecavir should not be used in this setting due to the potential for development of HIV resistance see section 4.4.
Entecavir was clastogenic to human lymphocyte cultures at concentrations substantially higher than those achieved clinically.
This observation is based on limited experience in 45 patients with Child-Pugh score≥ 7 at the start of entecavir treatment.
the known safety profile of entecavir.
It is not known whether entecavir, the active ingredient in Baraclude,
Exacerbations of hepatitis during and after discontinuation of entecavir therapy have also been reported see section 4.4 and c.
Baraclude should not be used in people who may be hypersensitive(allergic) to entecavir or any of the other ingredients.
Liver transplant recipients: renal function should be carefully evaluated before and during entecavir therapy in liver transplant recipients receiving cyclosporine or tacrolimus see section 5.2.
rtM250 decreases entecavir susceptibility in cell culture.
Do not take Baraclude if you are allergic(hypersensitive) to entecavir or any of the other ingredients of Baraclude.
This observation is based on limited experience in 45 patients with Child-Pugh score≥ 7 at the start of entecavir treatment.
These 14 patients had a lower rate of genotypic entecavir resistance(cumulative probability 18.8% through 5 years of follow-up)
Clinical resistance: patients in clinical trials initially treated with entecavir 0.5 mg(nucleoside-naive) or 1.0 mg(lamivudine-refractory)
patients in clinical trials initially treated with entecavir 0.5 mg(nucleoside-naive) or 1.0 mg(lamivudine-refractory)
HIV/ HBV co-infected patients receiving concomitant antiretroviral therapy: entecavir has been studied in 68 adults with HIV/ HBV co-infection receiving a lamivudine-containing HAART regimen see section 5.1.
rtM250 was identified in 3 patients treated with entecavir, 2 of whom experienced virologic breakthrough see table.
tenofovir or zidovudine were not antagonistic to the anti-HBV activity of entecavir over a wide range of concentrations.
In the presence of LVDr mutations, combination use of entecavir plus a second antiviral agent(which does not share cross-resistance with either lamivudine or entecavir) should be considered in preference to entecavir monotherapy see section 4.4.